

Pivot Pharmaceuticals Files Application for Canadian Stock Exchange (CSE) Listing

BOSTON, MA and VANCOUVER, BC - (Globe Newswire – July 12, 2017) – [Pivot Pharmaceuticals Inc. \(OTCQB: PVOTE\)](#) (“Pivot” or the “Company”), a biotechnology company engaged in the development and commercialization of therapeutic pharmaceutical products, is pleased to announce that the Company has applied to list its shares of common stock on the Canadian Securities Exchange (the “CSE”). Pivot’s common shares will continue to be listed in the United States on the OTCQB.

Pravin Chaturvedi, Ph.D., Pivot’s President and Chief Executive Officer, states that the decision to seek a dual listing in Canada on the CSE will allow the Company to significantly expand its shareholder base and gain access to capital markets in Canada. “Providing our shareholders with increased liquidity and even greater corporate compliance is of utmost importance to Pivot’s management team. In addition, as a “Designated Stock Exchange” all securities on the CSE are both RRSP and TFSA eligible.”

The CSE has not yet commented on the Company’s application nor has the CSE reviewed this press release. There can be no assurance that the CSE will approve the Company’s application for listing.

About Pivot Pharmaceuticals Inc.

Pivot is an emerging pharmaceutical company engaged in the development of novel therapies to address unmet medical needs in oncology and urology affecting women’s health. The Company has a strategic emphasis on the development of innovative drugs that will provide new treatment options for gynecological and breast cancers. Pivot has a global drug development platform that combines the strengths of the United States, Canada and India which allows accelerated drug development strategies to provide novel therapeutic options to address medical needs in women’s health.

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the level of business and consumer spending, the amount of sales of Pivot's products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot's expansion efforts, economic conditions in the industry, and the financial strength of Pivot's customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.



PIVOT

PHARMACEUTICALS

Contact:

Pivot Pharmaceuticals Inc.

Pravin Chaturvedi, PhD

Chief Executive Officer

Tel: (781) 935-1211

Email: info@pivotpharma.com

Web: www.pivotpharma.com

